Impact of Fas/Fasl Gene Polymorphisms on Susceptibility Risk and Imatinib Mesylate Treatment Response in Chronic Myeloid Leukaemia Patients. The gene discussed is FAS; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.